Risdiplam

ATC M09AX10 · 10 markets · 22 records

Risdiplam 10 markets · 22 records Forms

Filters

MarketAU 5 GB 3 US 2 CA 2 SG 2 ES 2 TW 2 HK 2 EU 1 FR 1

Strength

AU 5 records · 3 shown of 3 Source TGA、PBS Schedule API v3 (Department of +1 · Data as of 2026-10-28、live · some records have no stated strength · includes records with unknown status (not proof of sale)

5 mgtabletEVRYSDI+1EVRYSDI risdiplam 5 mg tablet blister pack also in GB·US·CA
+3Other 3 markets
SG ES TW
unknown
0.75 mg/1 mLpowderEVRYSDI also in FR
0.75 mg/mLpowderEVRYSDI risdiplam 0.75 mg/mL powder for oral solution bottle unknown

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商

With a brand name Con nombre comercial 有商品名有商品名EVRYSDI ×6

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包完整清單見資料包

GB 3 records · 1 shown of 1 Source NHSBSA dm+d · Data as of 2026-10-19 · some records have no stated strength

5 mgtabletEVRYSDI also in AU·US·CA
+3Other 3 markets
SG ES TW

2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商

With a brand name Con nombre comercial 有商品名有商品名Evrysdi 0.75mg/ml oral solution ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包完整清單見資料包

US 2 records · 2 shown of 2 Source openFDA NDC Directory · Data as of 2026-10-23

5 mgtabletEVRYSDI also in AU·GB·CA
+3Other 3 markets
SG ES TW
0.75 mgpowderEVRYSDI also in CA·TW

CA 2 records · 2 shown of 2 Source Health Canada Drug Product Databas · Data as of 2026-10-23

5 mgtabletEVRYSDI also in AU·GB·US
+3Other 3 markets
SG ES TW
0.75 mgpowderEVRYSDI also in US·TW

SG 2 records · 2 shown of 2 Source Health Sciences Authority (HSA) · Data as of 2026-08-07

5 mgtabletEVRYSDI also in AU·GB·US
+3Other 3 markets
CA ES TW
60 mgpowderEVRYSDI Powder for Oral Solution 0.75 mg/mL

ES 2 records · 2 shown of 2 Source CIMA (AEMPS) · Data as of live

5 mgtabletEVRYSDI also in AU·GB·US
+3Other 3 markets
CA SG TW
0.75 mg/1 mLliquidEVRYSDI

TW 2 records · 2 shown of 2 Source 衛生福利部食品藥物管理署（TFDA）全部藥品許可證資料集 · Data as of 2026-10-22

5 mgtabletEVRYSDI+1服脊立膜衣錠5毫克 also in AU·GB·US
+3Other 3 markets
CA SG ES
0.75 mgpowderEVRYSDI Powder for Oral Solution 0.75 mg/mL+1服脊立口服溶液用粉劑0.75毫克/毫升 also in US·CA

HK 2 records · 0 shown of 0 Source 衞生署藥物辦公室（香港）註冊藥劑製品名單 · Data as of 2026-10-23 · some records have no stated strength · includes records with unknown status (not proof of sale)

2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商

With a brand name Con nombre comercial 有商品名有商品名EVRYSDI ×6EVRYSDI Powder for Oral Solution 0.75 mg/mL ×3

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包完整清單見資料包

EU 1 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商

With a brand name Con nombre comercial 有商品名有商品名EVRYSDI ×6

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包完整清單見資料包

FR 1 records · 1 shown of 1 Source Base de données publique des médic · Data as of 2026-11-03

0.75 mg/1 mLpowderEVRYSDI 0,75 mg/mL, poudre pour solution buvable also in AU

Side-by-side table

Strength / form / release	US	GB	CA	AU	SG	ES	TW	HK	EU	FR
5 mg tablet	EVRYSDI	EVRYSDI	EVRYSDI	EVRYSDI EVRYSDI risdiplam 5 mg tablet blister pack	EVRYSDI	EVRYSDI	EVRYSDI 服脊立膜衣錠5毫克	not recorded	not recorded	not recorded
0.75 mg powder	EVRYSDI	not recorded	EVRYSDI	not recorded	not recorded	not recorded	EVRYSDI Powder for Oral Solution 0.75 mg/mL 服脊立口服溶液用粉劑0.75毫克/毫升	not recorded	not recorded	not recorded
0.75 mg/1 mLRecorded as: 750 microgram/1 mL powder	not recorded	not recorded	not recorded	EVRYSDI	not recorded	not recorded	not recorded	not recorded	not recorded	EVRYSDI 0,75 mg/mL, poudre pour solution buvable
0.75 mg/1 mL liquid	not recorded	not recorded	not recorded	not recorded	not recorded	EVRYSDI	not recorded	not recorded	not recorded	not recorded
60 mg powder	not recorded	not recorded	not recorded	not recorded	EVRYSDI Powder for Oral Solution 0.75 mg/mL	not recorded	not recorded	not recorded	not recorded	not recorded
0.75 mg/mL powder	not recorded	not recorded	not recorded	EVRYSDI risdiplam 0.75 mg/mL powder for oral solution bottle	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded
not disclosed unknown	not recorded	not recorded	not recorded	EVRYSDI	not recorded	not recorded	not recorded	EVRYSDI EVRYSDI Powder for Oral Solution 0.75 mg/mL	EVRYSDI	not recorded
not disclosed liquid	not recorded	Evrysdi 0.75mg/ml oral solution	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded	not recorded

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

3 more strength/form rows are recorded only in GB · SG · ES and are not shown in this table. Hay 3 filas de concentración/forma registradas solo en GB · SG · ES que no se muestran en esta tabla. 另有 3 个规格/剂型仅在 GB · SG · ES 有记录（未在本表显示）。另有 3 個規格/劑型僅在 GB · SG · ES 有記錄（未在本表顯示）。

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.

Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.